{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:41:52Z","timestamp":1788918112527,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303179"],"award-info":[{"award-number":["82303179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400428"],"award-info":[{"award-number":["82400428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82002834"],"award-info":[{"award-number":["82002834"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270830"],"award-info":[{"award-number":["82270830"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81871307"],"award-info":[{"award-number":["81871307"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373144"],"award-info":[{"award-number":["82373144"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2024AFB626"],"award-info":[{"award-number":["2024AFB626"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"crossref","award":["2024AFB062"],"award-info":[{"award-number":["2024AFB062"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Hubei Province Postdoctoral Innovation Practice Program","award":["2023-36"],"award-info":[{"award-number":["2023-36"]}]},{"name":"Westlake Omics Junior Clinician Support Program","award":["2021"],"award-info":[{"award-number":["2021"]}]},{"name":"State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases","award":["2024; no.17"],"award-info":[{"award-number":["2024; no.17"]}]},{"name":"Hubei Provincial Department of Science and Technology Key Innovation Program","award":["2021BCA142"],"award-info":[{"award-number":["2021BCA142"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Dysfunction of cytotoxic T cells (CTL) remains a major cause of tumor immune evasion and is correlated with poor cancer survival. Here, we found that increased soluble form of ICOSL (sICOSL) induced CTL dysfunction and was associated with shorter survival of patients with breast cancer. sICOSL emerged as a formidable adversary to CTLs, by directly triggering ICOS internalization and subsequent degradation\u2014a critical blow to the co-stimulatory machinery essential for CTL activation. Our research shows that dipeptidyl peptidase-4 (DPP4) mainly breaks down sICOSL. Notably, certain chemotherapeutic drugs activate the histone methyltransferase Enhancer of zeste homolog 2 (EZH2), which in turn suppresses DPP4 expression. To address this issue, we have developed nanobody-DPP4 fusion proteins that can specifically degrade sICOSL, achieving substrate selectivity and tumor targeting. Overall, This work unveils that sICOSL orchestrates CTL dysfunction, and establishs targeted degradation of sICOSL as a new strategy for immunotherapy.<\/jats:p>","DOI":"10.1186\/s40164-025-00692-x","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T09:11:10Z","timestamp":1753348270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction"],"prefix":"10.1186","volume":"14","author":[{"given":"Zhenghao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobing","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"issue":"1","key":"692_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"692_CR2","doi-asserted-by":"publisher","first-page":"j5913","DOI":"10.1136\/bmj.j5913","volume":"360","author":"JS Vaidya","year":"2018","unstructured":"Vaidya JS, Massarut S, Vaidya HJ, Alexander EC, Richards T, Caris JA, et al. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018;360:j5913.","journal-title":"BMJ"},{"issue":"1","key":"692_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-022-00363-1","volume":"12","author":"L Guo","year":"2023","unstructured":"Guo L, Kong D, Liu J, Zhan L, Luo L, Zheng W, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"692_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"issue":"36","key":"692_CR5","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.19.00693","volume":"37","author":"P Sharma","year":"2019","unstructured":"Sharma P, Barlow WE, Godwin AK, Parkes EE, Knight LA, Walker SM, et al. Validation of the Dna damage immune response signature in patients with triple-negative breast cancer from the swog 9313c trial. J Clin Oncol. 2019;37(36):3484\u201392.","journal-title":"J Clin Oncol"},{"issue":"12","key":"692_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1084\/jem.20050915","volume":"202","author":"N Casares","year":"2005","unstructured":"Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202(12):1691\u2013701.","journal-title":"J Exp Med"},{"issue":"2","key":"692_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17(2):97\u2013111.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"692_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","volume":"21","author":"L Bracci","year":"2014","unstructured":"Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. 2014;21(1):15\u201325.","journal-title":"Cell Death Differ"},{"issue":"9","key":"692_CR9","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","volume":"17","author":"N Nagarsheth","year":"2017","unstructured":"Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559\u201372.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"692_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","volume":"6","author":"D Gu","year":"2018","unstructured":"Gu D, Ao X, Yang Y, Chen Z, Xu X. Soluble immune checkpoints in cancer: production, function and biological significance. J Immunother Cancer. 2018;6(1):132.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"692_CR11","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1038\/oncsis.2017.82","volume":"6","author":"EL Kavanagh","year":"2017","unstructured":"Kavanagh EL, Lindsay S, Halasz M, Gubbins LC, Weiner-Gorzel K, Guang MHZ, et al. Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells. Oncogenesis. 2017;6(10):e388.","journal-title":"Oncogenesis"},{"issue":"7851","key":"692_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","volume":"591","author":"MJ Watson","year":"2021","unstructured":"Watson MJ, Vignali P, Mullett SJ, Overacre-Delgoffe AE, Peralta RM, Grebinoski S, et al. Metabolic support of tumour-infiltrating regulatory t cells by lactic acid. Nature. 2021;591(7851):645\u201351.","journal-title":"Nature"},{"issue":"1","key":"692_CR13","doi-asserted-by":"publisher","first-page":"e4049","DOI":"10.1136\/jitc-2021-004049","volume":"10","author":"Z Wu","year":"2022","unstructured":"Wu Z, Xi Z, Xiao Y, Zhao X, Li J, Feng N, et al. Tsh-tshr axis promotes tumor immune evasion. J Immunother Cancer. 2022;10(1):e4049.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"692_CR14","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41419-022-05048-5","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z, Xu Z, Zhou X, Li H, Zhao L, Lv Y, et al. Sgrp78 enhances selective autophagy of monomeric tlr4 to regulate myeloid cell death. Cell Death Dis. 2022;13(7):587.","journal-title":"Cell Death Dis"},{"issue":"21","key":"692_CR15","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1016\/j.cell.2021.09.006","volume":"184","author":"X Wang","year":"2021","unstructured":"Wang X, Tokheim C, Gu SS, Wang B, Tang Q, Li Y, et al. In vivo crispr screens identify the e3 ligase cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021;184(21):5357\u201374.","journal-title":"Cell"},{"key":"692_CR16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2016.00304","volume":"7","author":"DJ Wikenheiser","year":"2016","unstructured":"Wikenheiser DJ, Stumhofer JS. Icos co-stimulation: friend or foe? Front Immunol. 2016;7:304.","journal-title":"Front Immunol"},{"issue":"6816","key":"692_CR17","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/35051113","volume":"409","author":"A Tafuri","year":"2001","unstructured":"Tafuri A, Shahinian A, Bladt F, Yoshinaga SK, Jordana M, Wakeham A, et al. Icos is essential for effective t-helper-cell responses. Nature. 2001;409(6816):105\u20139.","journal-title":"Nature"},{"issue":"7","key":"692_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.4049\/jimmunol.1700833","volume":"199","author":"JC Lownik","year":"2017","unstructured":"Lownik JC, Luker AJ, Damle SR, Cooley LF, El SR, Hutloff A, et al. Adam10-mediated Icos ligand shedding on b cells is necessary for proper t cell Icos regulation and t follicular helper responses. J Immunol. 2017;199(7):2305\u201315.","journal-title":"J Immunol"},{"key":"692_CR19","doi-asserted-by":"crossref","unstructured":"Enz N, Vliegen G, De Meester I, Jungraithmayr W. Cd26\/dpp4 - a potential biomarker and target for cancer therapy. Pharmacol Ther. 2019;198(135\u2013\u200959.","DOI":"10.1016\/j.pharmthera.2019.02.015"},{"issue":"2","key":"692_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim KH, Roberts CWM. Targeting ezh2 in cancer. Nat Med. 2016;22(2):128\u201334.","journal-title":"Nat Med"},{"issue":"2","key":"692_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14712598.2020.1693540","volume":"20","author":"F Amatore","year":"2020","unstructured":"Amatore F, Gorvel L, Olive D. Role of inducible co-stimulator (icos) in cancer immunotherapy. Expert Opin Biol Ther. 2020;20(2):141\u201350.","journal-title":"Expert Opin Biol Ther"},{"issue":"12","key":"692_CR22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim S, Chung W, Im S, Park YH, Hegg R, et al. Trastuzumab Deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"16","key":"692_CR23","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab Govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384(16):1529\u201341.","journal-title":"N Engl J Med"},{"issue":"7403","key":"692_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346\u201352.","journal-title":"Nature"},{"issue":"10","key":"692_CR25","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2006.07.1522","volume":"25","author":"S Loi","year":"2007","unstructured":"Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in Estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007;25(10):1239\u201346.","journal-title":"J Clin Oncol"},{"issue":"7249","key":"692_CR26","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459(7249):1005\u20139.","journal-title":"Nature"},{"issue":"6","key":"692_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","volume":"26","author":"DA Braun","year":"2020","unstructured":"Braun DA, Hou Y, Bakouny Z, Ficial M, Sant Angelo M, Forman J, et al. Interplay of somatic alterations and immune infiltration modulates response to pd-1 Blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909\u201318.","journal-title":"Nat Med"},{"issue":"2","key":"692_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, et al. Distinct immune cell populations define response to anti-pd-1 monotherapy and anti-pd-1\/anti-ctla-4 combined therapy. Cancer Cell. 2019;35(2):238\u201355.","journal-title":"Cancer Cell"},{"issue":"2","key":"692_CR29","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/s41416-020-01123-w","volume":"124","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Yu M, Jing Y, Cheng J, Zhang C, Cheng L, et al. Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. Br J Cancer. 2021;124(2):414\u201324.","journal-title":"Br J Cancer"},{"issue":"6","key":"692_CR30","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, et al. Chemotherapy induces enrichment of cd47(+)\/cd73(+)\/pdl1(+) immune evasive triple-negative breast cancer cells. Proc Natl Acad Sci U S A. 2018;115(6):E1239\u201348.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"692_CR31","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1016\/j.cell.2022.03.033","volume":"185","author":"P Baldominos","year":"2022","unstructured":"Baldominos P, Barbera-Mourelle A, Barreiro O, Huang Y, Wight A, Cho J, et al. Quiescent cancer cells resist t cell attack by forming an immunosuppressive niche. Cell. 2022;185(10):1694\u2013708.","journal-title":"Cell"},{"issue":"1","key":"692_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.immuni.2021.11.017","volume":"55","author":"C Peng","year":"2022","unstructured":"Peng C, Huggins MA, Wanhainen KM, Knutson TP, Lu H, Georgiev H, et al. Engagement of the costimulatory molecule Icos in tissues promotes establishment of cd8\u2009+\u2009tissue-resident memory t cells. Immunity. 2022;55(1):98\u2013114.","journal-title":"Immunity"},{"issue":"13","key":"692_CR33","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1158\/0008-5472.CAN-15-3412","volume":"76","author":"TC Metzger","year":"2016","unstructured":"Metzger TC, Long H, Potluri S, Pertel T, Bailey-Bucktrout SL, Lin JC, et al. Icos promotes the function of cd4\u2009+\u2009effector t cells during anti-ox40\u2013mediated tumor rejection. Cancer Res. 2016;76(13):3684\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"692_CR34","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2020.02.015","volume":"180","author":"Y Lu","year":"2020","unstructured":"Lu Y, Zhao Q, Liao J, Song E, Xia Q, Pan J, et al. Complement signals determine opposite effects of b cells in chemotherapy-induced immunity. Cell. 2020;180(6):1081\u201397.","journal-title":"Cell"},{"issue":"9","key":"692_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, Mcarthur H, Kummel S, Bergh J, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"22","key":"692_CR36","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"2","key":"692_CR37","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","volume":"31","author":"EE Gardner","year":"2017","unstructured":"Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, et al. Chemosensitive relapse in small cell lung cancer proceeds through an ezh2-slfn11 axis. Cancer Cell. 2017;31(2):286\u201399.","journal-title":"Cancer Cell"},{"issue":"7546","key":"692_CR38","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nature14122","volume":"520","author":"CM Fillmore","year":"2015","unstructured":"Fillmore CM, Xu C, Desai PT, Berry JM, Rowbotham SP, Lin YJ, et al. Ezh2 Inhibition sensitizes brg1 and Egfr mutant lung tumours to topoii inhibitors. Nature. 2015;520(7546):239\u201342.","journal-title":"Nature"},{"issue":"9","key":"692_CR39","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1158\/2159-8290.CD-19-1493","volume":"10","author":"G Deblois","year":"2020","unstructured":"Deblois G, Tonekaboni S, Grillo G, Martinez C, Kao YI, Tai F, et al. Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast cancer. Cancer Discov. 2020;10(9):1312\u201329.","journal-title":"Cancer Discov"},{"issue":"4","key":"692_CR40","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.7150\/thno.48101","volume":"11","author":"Y Wen","year":"2021","unstructured":"Wen Y, Hou Y, Yi X, Sun S, Guo J, He X, et al. Ezh2 activates chk1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells. Theranostics. 2021;11(4):1795\u2013813.","journal-title":"Theranostics"},{"issue":"41","key":"692_CR41","first-page":"suppl","volume":"6","author":"HA Maha","year":"2023","unstructured":"Maha HA, Hussain MKPS. A pilot study of Tazemetostat and pembrolizumab in advanced urothelial carcinoma (etctn 10183). J Clin Oncol. 2023;6(41):suppl.","journal-title":"J Clin Oncol"},{"issue":"7","key":"692_CR42","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","volume":"22","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, et al. Combination of Atezolizumab and Tazemetostat in patients with relapsed\/refractory diffuse large b-cell lymphoma: results from a phase Ib study. Clin Lymphoma Myeloma Leuk. 2022;22(7):504\u201312.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"692_CR43","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41573-023-00833-z","volume":"23","author":"JA Wells","year":"2024","unstructured":"Wells JA, Kumru K. Extracellular targeted protein degradation: an emerging modality for drug discovery. Nat Rev Drug Discov. 2024;23(2):126\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"692_CR44","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41587-023-01840-6","volume":"42","author":"K Pedram","year":"2024","unstructured":"Pedram K, Shon DJ, Tender GS, Mantuano NR, Northey JJ, Metcalf KJ, et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat Biotechnol. 2024;42(4):597\u2013607.","journal-title":"Nat Biotechnol"},{"issue":"14","key":"692_CR45","doi-asserted-by":"publisher","first-page":"7942","DOI":"10.3390\/ijms23147942","volume":"23","author":"Y Hu","year":"2022","unstructured":"Hu Y, Wang Y, Lin J, Wu S, Lv H, Ji X, et al. Identification and characterization of specific nanobodies against trop-2 for tumor targeting. Int J Mol Sci. 2022;23(14):7942.","journal-title":"Int J Mol Sci"},{"key":"692_CR46","doi-asserted-by":"publisher","first-page":"865596","DOI":"10.3389\/fimmu.2022.865596","volume":"13","author":"Z Wu","year":"2022","unstructured":"Wu Z, Zhou J, Xiao Y, Ming J, Zhou J, Dong F, et al. Cd20\u2009+\u2009cd22\u2009+\u2009adam28\u2009+\u2009b cells in tertiary lymphoid structures promote immunotherapy response. Front Immunol. 2022;13:865596.","journal-title":"Front Immunol"},{"key":"692_CR47","doi-asserted-by":"crossref","unstructured":"Yu K, Wang Z, Wu Z, Tan H, Mishra A, Peng J. High-throughput profiling of proteome and posttranslational modifications by 16-plex Tmt labeling and mass spectrometry. Methods Mol Biol. 2021;2228:(205\u2013\u200924.","DOI":"10.1007\/978-1-0716-1024-4_15"},{"issue":"7","key":"692_CR48","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888\u2013902.","journal-title":"Cell"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00692-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00692-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T23:30:23Z","timestamp":1757287823000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00692-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00692-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Blood from healthy donors were obtained from the Wuhan Union Hospital with IRB approval by the Ethical Committee of the Tongji Medical College of Huazhong University of Science and Technology. Informed written consent from all participants or next of kin was obtained prior to the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors understand Journal of Experimental & Clinical Cancer Research is an open access journal that levies an article processing charge per articles accepted for publication. By submitting my article the authors agree to pay this charge in full if my article is accepted for publication. The results\/data\/figures in this manuscript have not been published elsewhere, nor are they under consideration (from you or one of your Contributing Authors) by another publisher. The authors have read the Nature Portfolio journal policies on author responsibilities and submit this manuscript in accordance with those policies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}